Fundraising FoxBroadOak Capital Partners — 2021 Investments
1 investments dated 2021 · listed companies and verified rows first · show all
KromaTiDkromatid.cominApr 2021
Kromatid provides single-cell structural genomic analysis tools for cell and gene therapy companies, enabling assessment of genomic integrity and identification of complex structural rearrangements during therapy development.
AI & Machine LearningBiotechDeep TechMedical DevicesLongmont, US
Andrew Jost(Executive Officer)James Chomas(Executive Officer, Director)Christopher Tompkins(Executive Officer, Director)Susan Bailey(Executive Officer)Joel Bedford(Director)
BoardTerry Opgenorth(Director)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.